Page 2 - Simon Jose News Today

Investegate announcements from Idorsia Pharmaceuticals Ltd, Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

26.01.2022 - Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant ... Seite 1

Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the ...

131.3 US GAAP revenue of CHF 7 million in the first quarter of 2021 consisted of contract revenue recognized in connection with the collaboration agreements with Neurocrine Biosciences, Inc. (CHF 1 million), Janssen Biotech, Inc. (CHF 3 million), Roche (CHF 2 million) and Mochida Pharmaceutical Co., Ltd (CHF 1 million) compared to a revenue of CHF 5 million in the first quarter of 2020. US GAAP operating expenses in the first quarter of 2021 amounted to CHF 129 million (CHF 116 million in the f...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Idorsia announces financial results for the first quarter 2021 – substantial progress made ... Idorsia Pharmaceuticals LtdApril 22, 2021 GMT Allschwil, Switzerland – April 22, 2021 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first quarter of 2021. Business highlights Daridorexant new drug application (NDA) submitted to the US FDA in January 2021 and has been accepted for...

Idorsia Pharmaceuticals Ltd: Idorsia announces financial results for 2020 - a successful year marked by outstanding clinical data Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year 2020. Business highlights Positive results in the Phase 3 program of daridorexant, demonstrating improved overall sleep and daytime functioning of patients with insomnia Daridorexant new drug application (NDA) submitted to the US FDA on January 8, 2021 Positive results in the Japanese reg...

131.2 US GAAP revenue of CHF 72 million in 2020 consisted of contract revenue recognized in connection with the collaboration agreements with Neurocrine Biosciences, Inc. (CHF 50 million), Janssen Biotech, Inc. (CHF 11 million), Roche (CHF 6 million), Mochida Pharmaceutical Co., Ltd (CHF 3 million) and Santhera Pharmaceuticals Ltd (CHF 2 million) compared to a revenue of CHF 24 million in 2019. US GAAP operating expenses in 2020 amounted to CHF 482 million (CHF 506 million in 2019), of which CH...